Therapeutic Resistance
Therapeutic Resistance - Related Videos
01:22
Resistivity
0 Views •
2023
When a voltage is applied to a conductor, an electrical field is generated, and charges in the conductor feel the force due to the electrical field. The current density that results depends on the electrical field and the properties of the material. In some materials, including metals at a given temperature, the current density is approximately proportional to the electrical field. In these cases, the current density can be modeled as: where σ is the electrical conductivity and is represented...
01:19
Resistance
0 Views •
2023
When a current moves through any conductor, the conductor causes some level of difficulty for the current to flow. The measure of that difficulty is known as the resistance of the material and is represented by R. Every material has its own resistance. In the case of conductors, heat is emitted whenever a current passes through them. Resistance depends on the resistivity of the material. Resistivity is a characteristic of the material used to fabricate electrical components, whereas the...
01:13
Therapeutic Index
0 Views •
2025
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
06:30
Bioassays for Monitoring Insecticide Resistance
0 Views •
Cited by 45 •
2010
This manuscript demonstrates and discusses techniques used to survey pesticide susceptibility and detect resistance to contact and systemic pesticides in arthropod pests.
08:46
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
0 Views •
Cited by 2 •
2015
Drug resistance to targeted therapeutics is widespread and the need to identify mechanisms of resistance--prior to or following clinical onset--is critical for guiding alternative clinical management strategies. Here, we present a protocol to couple derivation of drug-resistant lines in vitro with sequencing to expedite discovery of these mechanisms.
FAQs
Treatment can act as a selective pressure: susceptible cells or pathogens are inhibited, while a pre-existing resistant variant survives and becomes more prominent. This process does not require every member of the population to acquire resistance at the same time. Recognizing selection helps explain why treatment may initially work yet later lose effectiveness or be followed by disease recurrence.
Several changes can reduce treatment impact, including mutations that alter a drug target, reduced uptake into the affected cell, increased removal of the treatment, or substitution of the inhibited pathway. These mechanisms interfere with different stages of treatment action. Distinguishing among them is important because the biological cause of resistance influences how researchers design new drugs or combination therapies.
Resistance may arise not only from changes within the abnormal cell or pathogen population but also from protection provided by surrounding cells and tissues. This surrounding environment can help the population withstand treatment even when the treatment target itself has not changed. Such protection broadens the investigation beyond the resistant population and supports studying tissue context alongside cellular mechanisms.
When resistant cells or pathogens remain viable during treatment, the disease may not be fully controlled. The surviving population can then contribute to renewed disease after the initial response, making recurrence a biologically informative outcome rather than simply an unexplained clinical event. Studying the resistance mechanism helps connect treatment failure with specific changes in targets, pathways, uptake, removal, or protective surroundings.
Researchers can monitor treatment response together with resistance biomarkers, which are measurable indicators associated with a resistant population or mechanism. This approach helps identify whether resistance is emerging or already present and can connect biological findings with changes in treatment effectiveness. Monitoring supports decisions about combination therapies, next-generation drug design, and adaptive treatment strategies.
Combination therapies are used as a strategy for addressing resistance mechanisms that allow a population to withstand one treatment. By considering more than one biological vulnerability, researchers can design approaches that respond to target alteration, pathway substitution, altered drug handling, or protective effects from surrounding cells and tissues. The goal is to improve control when a single treatment has limited effectiveness.
Adaptive treatment strategies use information about resistance and changing treatment responses to guide how therapy is approached over time. Their development depends on understanding which resistant variants or mechanisms are present and how treatment selects for them. This makes resistance monitoring relevant not only for explaining failure but also for designing treatment plans intended to respond to evolving disease populations.
The concept is relevant across cancer, infectious diseases, and other conditions in which treatment may fail or disease may recur. In cancer, researchers may examine abnormal cell populations, altered targets, substituted pathways, and tissue protection. In infectious disease research, the same broader framework supports investigation of pathogen survival under treatment, while biomarker studies help guide future therapies.